Molecular pharmacology of sunitinib and vandetanib, two tyrosine kinase inhibitors, in Medullary Thyroid Carcinoma

Medullary thyroid carcinoma (MTC) accounts for 5-8% of all thyroid cancers and occurs as either a sporadic form or in a familial context (25% of cases). Mutations which activate the RET proto-oncogene, encoding a tyrosine kinase receptor, are responsible for familial forms and are also detected in one-third of sporadic tumors. MTC patients with local disease may be cured after initial surgery, but persistent or recurrent disease occurs in half of cases, and distant metastases are the major cause of tumor related death. Up to now there is no effective systemic treatment and new therapeutic strategies are needed for locally advanced or metastatic MTC patients. The constitutive activation of RET is crucial in MTC pathogenesis and led to the development of small compounds targeting its tyrosine kinase activity (TKI). Gaining an understanding of how cancer cells respond to drugs is challenging to improve clinical use of these new therapeutic agents. In this context, we aimed to characterize molecular mechanisms of action of sunitinib and vandetanib, two TKIs currently evaluated in MTC patients. Our results, in in vitro as well as in vivo MTC models based on the RETC634W TT cell line, demonstrate that sunitinib and vandetanib has similar antiproliferative, antitumoral and antiangiogenic properties. Using the Reverse Phase Protein Array (RPPA) large-scale technology, we identified major signalling pathways inhibited after TKIs’ treatment. Expression microarrays allowed us to investigate signaling pathways modified after sunitinib and vandetanib treatment and to show that TKIs’ treatment induced major changes in the expression of genes involved in tissue invasion and metastasis. We identified encoding secreted proteins as candidate soluble biomarkers of response and, among them, we demonstrated that metastatic MTC patients presented increased serum levels of IL-8 and TGF-2. Three modalities for determining early responses to targeted agents in MTC patients were evaluated. First, a sensitive mass spectrometry assay was developed for the quantitation of vandetanib, and applied in MTC patients, showing a potential relationship between toxic side-effects and vandetanib serum levels and suggesting that therapeutic drug monitoring may be a useful tool for MTC patients’ follow-up. Then, candidate biomarkers were investigated in MTC patients underlying the potential use of IL-8 as prognostic marker. Finally, using doppler imaging in xenografted mice model, we confirmed the utility of imaging techniques in clinical evaluation of TKI’s response.

Data and Resources

Additional Info

Field Value
Source https://theses.hal.science/tel-00829093
Author Broutin, Sophie
Maintainer CCSD
Last Updated May 10, 2026, 22:01 (UTC)
Created May 10, 2026, 22:01 (UTC)
Identifier NNT: 2011PA11T053
Language fr
Rights https://about.hal.science/hal-authorisation-v1/
contributor Génomes et cancer (GC (FRE2939)) ; Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Centre National de la Recherche Scientifique (CNRS)
creator Broutin, Sophie
date 2011-09-27T00:00:00
harvest_object_id b16e77bb-5661-4a10-b290-2784c05251be
harvest_source_id 3374d638-d20b-4672-ba96-a23232d55657
harvest_source_title test moissonnage SELUNE
metadata_modified 2026-03-30T00:00:00
set_spec type:THESE